Zoledronic Acid Altan 5mg/100ml Solution for Infusion (Zoledronic Acid)
Patient Card

This reminder card contains important safety information that you need to be aware of before and during treatment with zoledronic acid (5mg solution for infusion).

Your doctor has recommended that you receive zoledronic acid, which is used to treat post-menopausal women and adult men with osteoporosis or osteoporosis caused by treatment with steroids, and Paget's disease of the bone in adults. These diseases involve thinning and weakening of the bones so they may break more easily.

A side effect called osteonecrosis of the jaw (ONJ) (severe bone damage in the jaw) has been reported very rarely in patients receiving zoledronic acid for osteoporosis. ONJ can also occur after stopping treatment.

It is important to try and prevent ONJ developing as it is a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions you should take:

Before starting treatment:
Tell your doctor/nurse (health care professional) if you have any problems with your mouth or teeth. Your doctor may ask you to undergo a dental examination if you:

- were previously treated with a bisphosphonate
- are taking medicines called corticosteroids (such as prednisolone or dexamethasone)
- are a smoker
- have cancer
- have not had a dental check up for a long time
- have problems with your mouth or teeth

While being treated:
- You should maintain good oral hygiene, brush your teeth regularly and receive routine dental check-ups. If you wear dentures you should make sure these fit properly.
- If you are under dental treatment or will undergo dental surgery (e.g. tooth extraction(s)) inform your doctor and tell your dentist that you are being treated with zoledronic acid.
- Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.

Please read the package leaflet that comes with your medicine for further information.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

Please contact the Marketing Authorisation Holder as below:
Altan Pharmaceuticals SAU, C/ Cólquide, 6- Portal 2, 2ª planta- ofi F (Edificio Prisma)
Localidad 28230 · Las Rozas · Madrid
Tel: +34 91 637 06 60
Email: farmacovigilancia@altanpharma.com

Alternatively, any suspected adverse reactions can also be reported to:
Malta Medicines Authority Post-Licensing Directorate, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Ġwann SGN 3000, Malta or online via the ADR Reporting Website: www.medicinesauthority.gov.mt/adrportal